Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound

This article was originally published in The Pink Sheet Daily

Executive Summary

Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.

You may also be interested in...



U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes

The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.

U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes

The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.

Novartis And Antisoma's ASA404 Stumbles Badly In A Phase III Lung Cancer Trial

Prospects for what was thought to be a promising first-in-class lung cancer treatment dim after a Phase III trial is halted early due to futility of improving survival.

Related Content

Topics

UsernamePublicRestriction

Register

PS071769

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel